CERTHealthcare · Health Information ServicesThe 13 Wall Street analysts covering Certara, Inc. hold a median 12-month price target of $9 — -18.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 65 of 100 as at 4 Nov 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Certara, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (91): The share count has been shrinking and the company is not leaning on new borrowing.
Growth (39): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (37): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on CERT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −18.8% from it.
Of the 20 most recent actions, 4 moved their price target up and 6 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 Oct 2026 | Keybanc | Maintains | Overweight | $9.00 → $12 |
| 13 Oct 2026 | TD Cowen | Maintains | Buy | $9.00 → $11 |
| 7 Oct 2026 | Barclays | Maintains | Equal-Weight | $7.50 → $9.00 |
| 7 Oct 2026 | Barclays | Maintains | Equal-Weight | — |
| 30 Sept 2026 | UBS | Downgrade | Neutral | $10 |
| 30 Sept 2026 | UBS | Downgrade | Neutral | — |
| 5 Aug 2026 | Barclays | Maintains | Equal-Weight | — |
| 5 Aug 2026 | Barclays | Maintains | Equal-Weight | $6.50 → $7.50 |
| 12 May 2026 | Baird | Maintains | Neutral | — |
| 12 May 2026 | Baird | Maintains | Neutral | $7.00 → $6.00 |
| 12 May 2026 | Barclays | Maintains | Equal-Weight | $8.00 → $6.50 |
| 12 May 2026 | Barclays | Maintains | Equal-Weight | — |
| 12 May 2026 | BMO Capital | Maintains | Market Perform | — |
| 12 May 2026 | BMO Capital | Maintains | Market Perform | $7.00 → $6.00 |
| 12 May 2026 | Craig-Hallum | Maintains | Hold | — |
| 12 May 2026 | Craig-Hallum | Maintains | Hold | $10 → $8.00 |
| 12 May 2026 | Morgan Stanley | Maintains | Equal-Weight | $11 → $10 |
| 12 May 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 12 May 2026 | Stephens & Co. | Maintains | Overweight | — |
| 12 May 2026 | Stephens & Co. | Maintains | Overweight | $10 → $9.00 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CERT appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Certara, Inc. returned −4.0% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 7% of US stocks
Cheaper than 30% of US stocks
Cheaper than 48% of US stocks
Cheaper than 16% of US stocks
Higher than 30% of US stocks
Higher than 26% of US stocks
Higher than 75% of US stocks
Higher than 31% of US stocks
Higher than 17% of US stocks
Higher than 42% of US stocks
Higher than 48% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Certara, Inc. has a market value of $1.7B and an enterprise value of $1.8B.
Revenue in the twelve months to 30 June 2026: $408.4M. The latest quarter grew 1.0% year on year.
Net income over the same four quarters: −$68.4M, a −16.7% net margin.
Diluted earnings per share, trailing twelve months: $−0.45.
Free cash flow in the twelve months to 30 June 2026: $54.6M, after $28.3M of capital spending.
Certara, Inc. spent $75.0M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 105.0×; forward P/E: 27.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Certara, Inc. employs 1,515 people — $270K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Certara, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Certara announced it will report third-quarter 2026 financial results before market open on November 5, 2026. Management will discuss the results on a conference call at 8:30 a.m. ET.
Why it matters — CERT watchers can note the scheduled release and call for the company’s third-quarter results.
Cerrado Gold Inc. (CERT:CA) held its Q2 2026 earnings call, and a transcript of the call has been published on Seeking Alpha.
Why it matters — The transcript provides CERT watchers with the company's full Q2 2026 commentary and management discussion.
Seeking Alpha published the transcript of Certara, Inc.'s (CERT) Q2 2026 earnings call. The transcript contains the company's presentation and discussion from its second-quarter earnings call.
Why it matters — The transcript gives CERT watchers access to management's full commentary on the quarter, beyond the headline earnings figures.
Certara reported second-quarter 2026 revenue of $93.3 million, up 1% year over year, as software growth offset a decline in services revenue. Management reaffirmed its full-year revenue outlook while outlining further changes to its commercial organization, cost structure, and artificial intelligence strategy.
Why it matters — A CERT watcher would care because the company reaffirmed its full-year revenue outlook while signaling continued restructuring of its commercial organization, cost structure, and AI strategy.
Certara reported Q2 earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.10 per share, though above the $0.07 per share earned a year ago. Revenues also lagged estimates in the quarter.
Why it matters — A CERT watcher would note that the quarter fell short of Wall Street's earnings and revenue expectations despite showing year-over-year earnings growth.
The 13 Wall Street analysts covering Certara, Inc. have a median 12-month price target of $9, with estimates ranging from $7 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 13 analysts covering Certara, Inc., 4 rate it a Buy, 9 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Certara, Inc. 65 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Certara, Inc. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (91 of 100).
No one can know that. What the data says: the median 12-month target from 13 analysts implies -18.8% from the last close, and Ticker Nerd's factor model ranks Certara, Inc. 65 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Certara, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CERT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $12 over the next 12 months.
Certara, Inc. returned -4.0% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Certara Inc. is a life sciences software and services company focused on biosimulation and model-informed drug development.
The most recent item we track (GlobeNewsWire, 26 Oct 2026): "Certara to Report Third Quarter 2026 Financial Results on November 5th, 2026". Certara announced it will report third-quarter 2026 financial results before market open on November 5, 2026. Management will discuss the results on a conference call at 8:30 a.m. ET.
Certara Inc. is a life sciences software and services company focused on biosimulation and model-informed drug development. Certara provides software tools and technology-enabled services that help pharmaceutical, biotechnology, and regulatory organizations model drug behavior, analyze pharmacokinetics and pharmacodynamics, and support clinical development and regulatory submissions. Its offerings include biosimulation platforms, clinical data automation and validation software, regulatory authoring and submission tools, and market access solutions. The company serves organizations across drug discovery, preclinical research, clinical research, and post-approval activities, supporting more data-driven decision-making throughout the drug development lifecycle. Certara Inc. plays a specialized role in the healthcare market by helping customers improve development efficiency, strengthen evidence generation, and navigate complex regulatory requirements.
CEO Mr. Jon Resnick · 1,515 employees · United States · https://www.certara.com
